AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14625121 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving HRT)
Number of subjects: 241
Study 11182960 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone care (three intervening telephone appointments scheduled)
Number of subjects: 512
Study 11182960 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 512
Study 8626941 — intervention group
Group type: EXPERIMENTAL
Intervention: GUSTO trial participants
Number of subjects: 12309
Study 8626941 — intervention group
Group type: EXPERIMENTAL
Intervention: LATE trial participants
Number of subjects: 12309
Study 8626941 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipants at GUSTO hospitals
Number of subjects: 12309
Study 8626941 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipants at LATE hospitals
Number of subjects: 12309
Study 1593561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygroscopic cervical dilators
Number of subjects: 74
Study 1593561 — intervention group
Group type: COMPARATOR
Intervention: Intracervical prostaglandin E2 (PGE2) gel
Number of subjects: 74
Study 1593561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygroscopic cervical dilators and Intracervical prostaglandin E2 (PGE2) gel
Number of subjects: 74
Study 2934579 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with flutamide and LHRH agonist (or orchiectomy)
Number of subjects: 87
Study 2934579 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy alone
Number of subjects: 87
Study 31439956 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids (n=77)
Number of subjects: 144
Study 31439956 — intervention group
Group type: COMPARATOR
Intervention: Control (n=67)
Number of subjects: 144
Study 29936668 — intervention group
Group type: EXPERIMENTAL
Intervention: CADence acoustic detection (AD) system
Number of subjects: 1013
Study 29936668 — intervention group
Group type: COMPARATOR
Intervention: Nuclear stress testing (objective performance criteria)
Number of subjects: 1013
Study 27830671 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prolidase activity
Number of subjects: 35
Study 27830671 — intervention group
Group type: EXPERIMENTAL
Intervention: Total oxidant status (TOS)
Number of subjects: 35
Study 27830671 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidative stress index (OSI)
Number of subjects: 35
Study 27830671 — intervention group
Group type: EXPERIMENTAL
Intervention: Total antioxidant status (TAS)
Number of subjects: 35
Study 25352732 — intervention group
Group type: EXPERIMENTAL
Intervention: Four tablets at full dose
Number of subjects: 15
Study 25352732 — intervention group
Group type: EXPERIMENTAL
Intervention: Two softgels at full dose
Number of subjects: 15
Study 25352732 — intervention group
Group type: EXPERIMENTAL
Intervention: One softgel at half-dose
Number of subjects: 15
Study 25352732 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc absorption
Number of subjects: 15
Study 22967121 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin/amoxicillin/esomeprazole
Number of subjects: 101
Study 22967121 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole/metronidazole/bismuth salt/tetracycline
Number of subjects: 101
Study 22967121 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-resistant strains
Number of subjects: 101
Study 22967121 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-susceptible strains
Number of subjects: 101
Study 20082201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower blepharoplasty with periorbital fat mobilization and arcus marginalis redrape
Number of subjects: 50
Study 20082201 — intervention group
Group type: COMPARATOR
Intervention: Conservatively standard fat‐resection lower blepharoplasty
Number of subjects: 50
Study 20082201 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 50
Study 18827122 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal insert 100
Number of subjects: 1308
Study 18827122 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal insert 50
Number of subjects: 1308
Study 18827122 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone vaginal insert
Number of subjects: 1308
Study 12735532 — intervention group
Group type: EXPERIMENTAL
Intervention: Home physiotherapy
Number of subjects: 40
Study 12735532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital physiotherapy
Number of subjects: 40
Study 12735532 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 40
Study 12735532 — intervention group
Group type: EXPERIMENTAL
Intervention: Home therapy
Number of subjects: 40
Study 12735532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital therapy
Number of subjects: 40
Study 10647713 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of hemorrhages and microaneurysms (h/ma) temporal to the macula (photographic field 3) as severe as or more severe than ETDRS standard photograph 1 (h/ma 3 >= 3)
Number of subjects: 3711
Study 10647713 — intervention group
Group type: EXPERIMENTAL
Intervention: Single examination for detecting PDR
Number of subjects: 3711
Study 10647713 — intervention group
Group type: EXPERIMENTAL
Intervention: Single examination for moderate NPDR or worse
Number of subjects: 3711
Study 10647713 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of any hard exudate within one disc diameter of the macular center
Number of subjects: 3711
Study 10647713 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard exudate of moderate or worse severity anywhere in the macular region (field 2)
Number of subjects: 3711
Study 9575669 — intervention group
Group type: EXPERIMENTAL
Intervention: c‐EOAE in noise-exposed individuals
Number of subjects: 122
Study 9575669 — intervention group
Group type: EXPERIMENTAL
Intervention: c‐EOAE spectrum analysis
Number of subjects: 122
Study 8398529 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and droperidol
Number of subjects: 50
Study 8398529 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 50
Study 2943643 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin K 2165
Number of subjects: 10
Study 2943643 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 10
Study 2943643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 10
Study 29637434 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced messages about safe sleep practices to prevent SIDS and suffocation
Number of subjects: 1194
Study 29637434 — intervention group
Group type: COMPARATOR
Intervention: Standard messages about safe sleep practices to reduce the risk of SIDS
Number of subjects: 1194
Study 26547291 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg biweekly (Q2W) or 420 mg monthly (QM)
Number of subjects: 404
Study 26547291 — intervention group
Group type: COMPARATOR
Intervention: Placebo Q2W or QM
Number of subjects: 404
Study 24767519 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-directed physical therapy (pdPT)
Number of subjects: 300
Study 24767519 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (ST)
Number of subjects: 300
Study 22831781 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (8 trains applied over two consecutive days)
Number of subjects: 0
Study 22831781 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 22831781 — intervention group
Group type: COMPARATOR
Intervention: Control group without stimulation
Number of subjects: 0
Study 19965537 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF
Number of subjects: 406
Study 19965537 — intervention group
Group type: COMPARATOR
Intervention: HD
Number of subjects: 406
Study 18480036 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage format (e.g., 12%)
Number of subjects: 16133
Study 18480036 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency format (e.g., 12 in 100)
Number of subjects: 16133
Study 18480036 — intervention group
Group type: COMPARATOR
Intervention: 1-in-n format (e.g., 1 in 8)
Number of subjects: 16133
Study 15900006 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analyses
Number of subjects: 2646
Study 15900006 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 2646
Study 15900006 — intervention group
Group type: COMPARATOR
Intervention: Epidemiological studies, nonsystematic review articles, decision and cost-effectiveness analyses
Number of subjects: 2646
Study 15900006 — intervention group
Group type: COMPARATOR
Intervention: Case reports
Number of subjects: 2646
Study 15900006 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analyses (limited to studies addressing treatment effects)
Number of subjects: 2646
Study 12847067 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet (27% total fat, 6% saturated fat) for 12 weeks
Number of subjects: 100
Study 12847067 — intervention group
Group type: COMPARATOR
Intervention: Control diet (37% total fat, 16% saturated fat) for 12 weeks
Number of subjects: 100
Study 12847067 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet (27% total fat, 6% saturated fat) for 12 weeks in participants with low baseline CRP
Number of subjects: 100
Study 12847067 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet (27% total fat, 6% saturated fat) for 12 weeks in participants with high baseline CRP
Number of subjects: 100
Study 10029478 — intervention group
Group type: EXPERIMENTAL
Intervention: Subperiosteal nasal floor augmentation with Surgicel
Number of subjects: 64
Study 10029478 — intervention group
Group type: COMPARATOR
Intervention: Control group (no subperiosteal pocket and no Surgicel)
Number of subjects: 64
Study 8659717 — intervention group
Group type: COMPARATOR
Intervention: Morphine 1 mg/mL
Number of subjects: 195
Study 8659717 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 1 mg/mL plus lidocaine 10 mg/mL
Number of subjects: 195
Study 8659717 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 1 mg/mL plus lidocaine 20 mg/mL
Number of subjects: 195
Study 1794158 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 150 mg/day administered at noon
Number of subjects: 40
Study 1794158 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 150 mg/day administered at morning or before bedtime
Number of subjects: 40
Study 1794158 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine administered three times a day by traditional, equally divided doses
Number of subjects: 40
Study 1794158 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 150 mg/day
Number of subjects: 40
Study 6363078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg (N10)
Number of subjects: 10
Study 6363078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg (N20)
Number of subjects: 10
Study 6363078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30906769 — intervention group
Group type: EXPERIMENTAL
Intervention: CASP8 SNP rs6704688
Number of subjects: 540
Study 30906769 — intervention group
Group type: EXPERIMENTAL
Intervention: CASP7 haplotype GC
Number of subjects: 540
Study 28368938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered-shaped cuff (Group T)
Number of subjects: 191
Study 28368938 — intervention group
Group type: COMPARATOR
Intervention: Cylindrical cuff (Group C)
Number of subjects: 191
Study 26922537 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 15mg/d
Number of subjects: 30
Study 26922537 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg/d
Number of subjects: 30
Study 26922537 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg/d + Ezetimibe 10mg/d
Number of subjects: 30
Study 23668824 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-containing toothpaste (3000 μg/mL TCS)
Number of subjects: 40
Study 23668824 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 40
Study 22196407 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 40
Study 22196407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 40
Study 19874111 — intervention group
Group type: EXPERIMENTAL
Intervention: Lawson vision intervention
Number of subjects: 88
Study 19874111 — intervention group
Group type: EXPERIMENTAL
Intervention: Phono-Graphix intervention
Number of subjects: 88
Study 19874111 — intervention group
Group type: COMPARATOR
Intervention: Parental Literacy Support (Control)
Number of subjects: 88
Study 19874111 — intervention group
Group type: EXPERIMENTAL
Intervention: Lawson and Phono-Graphix interventions
Number of subjects: 88
Study 17406798 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-containing radiochemotherapy (paclitaxel 25-35 mg/m² twice weekly)
Number of subjects: 42
Study 17406798 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation treatment administered to a total dose of 45-60 Gy
Number of subjects: 42
Study 14695786 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN (0.5 microg/body weight/week) and ribavirin (1,000 mg-1,200 mg/daily) for 48 weeks
Number of subjects: 15
Study 14695786 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN plus ribavirin
Number of subjects: 15
Study 11333004 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse in the family of origin
Number of subjects: 0
Study 11333004 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissociation
Number of subjects: 0
Study 11333004 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring codependency
Number of subjects: 0
Study 9208361 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg) administered alone
Number of subjects: 33
Study 9208361 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg) administered after ranitidine treatment
Number of subjects: 33
Study 9208361 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg) with cola beverage
Number of subjects: 33
Study 9208361 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine treatment (gastric pH at least 6.0)
Number of subjects: 33
Study 8119049 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline target concentration of 10 mg/L
Number of subjects: 174
Study 8119049 — intervention group
Group type: COMPARATOR
Intervention: Theophylline target concentration of 20 mg/L
Number of subjects: 174
Study 3301053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 3301053 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 0
Study 3301053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29310645 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 60
Study 29310645 — intervention group
Group type: COMPARATOR
Intervention: metformin
Number of subjects: 60
Study 27070727 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI, n = 145)
Number of subjects: 269
Study 27070727 — intervention group
Group type: COMPARATOR
Intervention: Assessment Only (AO, n = 124)
Number of subjects: 269
Study 24846807 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI quartile 1 (<24.5 kg/m²)
Number of subjects: 3579
Study 24846807 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI quartile 2 (24.5 to <27.1 kg/m²)
Number of subjects: 3579
Study 24846807 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI quartile 3 (27.1 to 30.1 kg/m²)
Number of subjects: 3579
Study 24846807 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI quartile 4 (>30.1 kg/m²)
Number of subjects: 3579
Study 23237436 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 PUFA treatment (1 g/day for 6 months)
Number of subjects: 140
Study 23237436 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy only)
Number of subjects: 140
Study 20354834 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg d(‐1) for 8 days prior to exercise trial and 600 mg on the day of exercise trial
Number of subjects: 15
Study 20354834 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 15
Study 18622600 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide (BNP) infusion at 16.2 pmol/min for 30 min
Number of subjects: 0
Study 18622600 — intervention group
Group type: COMPARATOR
Intervention: Atrial natriuretic peptide (ANP) infusion at 16.2 pmol/min for 30 min
Number of subjects: 0
Study 16317123 — intervention group
Group type: EXPERIMENTAL
Intervention: High-ALA diet (7 En% LA, 1.1 En% ALA)
Number of subjects: 54
Study 16317123 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-LA diet (3 En% LA, 0.4 En% ALA)
Number of subjects: 54
Study 16317123 — intervention group
Group type: COMPARATOR
Intervention: Control diet (7% of energy as LA and 0.4 En% as ALA)
Number of subjects: 54
Study 12598065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (15, 30 or 60 mg)
Number of subjects: 120
Study 12598065 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hirudin (intravenous)
Number of subjects: 120
Study 12598065 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (subcutaneous)
Number of subjects: 120
Study 12598065 — intervention group
Group type: COMPARATOR
Intervention: Ximelagatran (60 mg)
Number of subjects: 120
Study 12752357 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction interferon plus ribavirin (II + R)
Number of subjects: 218
Study 12752357 — intervention group
Group type: COMPARATOR
Intervention: Induction interferon plus placebo (II + P)
Number of subjects: 218
Study 9708720 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate 0.050% nasal spray, 50 microg, 4 times daily for 2 weeks
Number of subjects: 45
Study 9708720 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate 0.075% nasal spray, 75 microg, 4 times daily for 2 weeks
Number of subjects: 45
Study 9708720 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 45
Study 8570772 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol pretreatment
Number of subjects: 8
Study 8570772 — intervention group
Group type: COMPARATOR
Intervention: mCPP
Number of subjects: 8
Study 1982747 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% apraclonidine hydrochloride
Number of subjects: 20
Study 1982747 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50% apraclonidine hydrochloride
Number of subjects: 20
Study 1982747 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 20
Study 1982747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 359398 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (ICI 66082) 100 mg daily for 30 days
Number of subjects: 40
Study 359398 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 30 days
Number of subjects: 40
Study 31094935 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 90
Study 31094935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 28510350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised hypertonic saline (administered 38.7%–74.7% of the time in Ward A and Ward B)
Number of subjects: 286
Study 28510350 — intervention group
Group type: COMPARATOR
Intervention: Nebulised hypertonic saline (administered infrequently at 6.7% in Ward C)
Number of subjects: 286
Study 28510350 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (used in conjunction with nebulised hypertonic saline)
Number of subjects: 286
Study 23895463 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic silver alloy-coated silicone urinary catheters
Number of subjects: 742
Study 23895463 — intervention group
Group type: COMPARATOR
Intervention: Standard urinary catheters
Number of subjects: 742
Study 21768453 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin followed by docetaxel (EPI-DOC)
Number of subjects: 803
Study 21768453 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin alone (EPI × 6)
Number of subjects: 803
Study 21768453 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-DOC
Number of subjects: 803
Study 19295302 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0
Study 19295302 — intervention group
Group type: COMPARATOR
Intervention: Retrospective studies
Number of subjects: 0
Study 16881427 — intervention group
Group type: EXPERIMENTAL
Intervention: Prechop MPF
Number of subjects: 100
Study 16881427 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 100
Study 15504138 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine
Number of subjects: 0
Study 15504138 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study 11342919 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 56
Study 11342919 — intervention group
Group type: COMPARATOR
Intervention: Nonscreened controls
Number of subjects: 56
Study 11342919 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening detected tumors
Number of subjects: 56
Study 11342919 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent tumors
Number of subjects: 56
Study 11342919 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically detected organ confined tumors
Number of subjects: 56
Study 11342919 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized control tumors
Number of subjects: 56
Study 11342919 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic tumors
Number of subjects: 56
Study 9001307 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled indomethacin (3 mg/m2 body surface area)
Number of subjects: 9
Study 9001307 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 9
Study 8515850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg i.m. every 6 hours)
Number of subjects: 0
Study 8515850 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine (0.3 mg i.m. every 12 hours)
Number of subjects: 0
Study 2887613 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg h.s.
Number of subjects: 1031
Study 2887613 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg b.i.d.
Number of subjects: 1031
Study 2887613 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg b.i.d.
Number of subjects: 1031
Study 2887613 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 1031